1cP-MiPLA
Well-documented
Well-documented
Multiple authoritative sources agree on dosing and effects.
- 3 corroborating sources
- 2 ROAs with full dose ladders
- duration data present
- 19 combo interactions documented
- PubChem toxicity data
- classified Research-chemical
- 3 corroborating sources
- 2 ROAs with full dose ladders
- duration data present
- 19 combo interactions documented
- PubChem toxicity data
- classified Research-chemical
Summary
1cP-MiPLA (1-cyclopropionyl-N-methyl-N-isopropyllysergamide) is a novel lysergamide first appearing on research chemical markets around 2020. It acts as a prodrug that rapidly hydrolyzes to MiPLA, similar to how 1P-LSD converts to LSD. Potency is approximately 60-80% of LSD by weight; many users find 150 ug comparable to 100 ug LSD.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | 100-150µg | 150-200µg | 200-250µg | 300µg+ |
| Sublingual | 100-150µg | 150-200µg | 200-250µg | 300µg+ |
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset |
|---|---|---|---|---|
| Oral | 20-40 min | 45-90 min | 1-2 hrs | 1-2 hrs |
| Sublingual | 20-40 min | 45-90 min | 1-2 hrs | 1-2 hrs |
Effect Profile
Scores (1–10) curated from multiple sources:
- Effect keyword matching from PsychonautWiki catalog
- Weighted by importance: core (×3), major (×2), minor (×1)
Strong visuals and auditory effects with moderate headspace and body load
Tolerance
Tolerance Decay
Acute tolerance: develops within a single session — the reset numbers above apply after sustained heavy use, not after one binge. Within-session tachyphylaxis usually resets largely overnight.
Functional tolerance to lysergamides rises rapidly within a single session and decays over 5–14 days; acute redosing beyond ~45–60 min is typically inefficient. Cross‑tolerance is expected across serotonergic psychedelics that act via 5‑HT2A.
Cross-Tolerances
Effects
- Stimulation
- Physical euphoria
- Pupil dilation
- Temperature regulation suppression
- Increased perspiration
- Nausea
- Increased heart rate
- Increased blood pressure
- Seizure
- Muscle twitching
- Spontaneous bodily sensations
- Difficulty urinating
- Excessive yawning
- Muscle contractions
- Increased salivation
- Increased bodily temperature
- Stamina intensification
- Analysis enhancement
- Cognitive euphoria
- Emotion enhancement
- Wakefulness
- Motivation enhancement
- Novelty enhancement
- Conceptual thinking
- Unity and interconnectedness
- Laughter fits
- Increased sense of humor
- Immersion intensification
- Memory suppression
- Thought loops
- Delusion
- Time distortion
- Thought acceleration
- Machinescapes
- Depth perception distortions
- Thought loop
- Existential self-realization
- Emotion intensification
- Focus intensification
- Tactile enhancement
- Color enhancement
- Pattern recognition enhancement
- Visual acuity enhancement
- Tracers
- Increased music appreciation
- Increased libido
- Bodily control enhancement
- Color shifting
- Auditory acuity enhancement
- Appetite suppression
- Changes in felt bodily form
- Drifting
- After images
- Geometric visual patterns
- Mild internal hallucinations
- Auditory hallucination
- Auditory distortion
- Diffraction
- Symmetrical texture repetition
- Scenery slicing
- External hallucination
- Internal hallucination
- Autonomous entity
- Perspective hallucination
- Tactile intensification
Combinations
Cross-Check 1cP-MiPLA with another substanceHelpful Links
Report an issue or suggest an edit
Spotted incorrect or dangerous information, have a correction, a new study, or a useful addition for 1cP-MiPLA? Let us know. Reports are reviewed by moderators — this is not posted publicly.